Immunotherapeutic PD-1 by pembrolizumab monotherapy has achieved significant improvement on the survival of solid tumor patients, such as non-small-cell lung carcinoma, gastric cancer, renal cell carcinoma, melanoma, cervical cancer, and triple-negative breast cancer (24–26). This evidence concerns the gene PDCD1 and cervical carcinoma.